acqute coronary syndrome
Conditions
Interventions
Single antiplatelet:Aspirin, 75-150mmg, Q.D.
Low dose ticagrelor group:Aspirin, 75-150mmg, Q.D., combined with Ticagrelor, 60mg, B.I.D.
Clopidogrel group:Aspirin, 75-150mmg, Q.D., combined with Clopidogrel, 50-75mg, Q.D.
Sponsors
Fuwai Central China Cardiovascular Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. high-risk Chinese patients receiving PCI (DAPT score >= 2), aged 18-75 years, gender no limitation; 2. voluntary signing of informed consent; 3. Willing and able to receive 1 year follow-up.
Exclusion criteria
Exclusion criteria: 1. Allergic to aspirin and tegrillo; 2. Uncontrolled hypertension (> 180/110mmhg); 3. STEMI48 hours; 4. Patients with active bleeding within 3 months prior to enrollment and known bleeding tendency or coagulation disorder; 5. The increased risk of bleeding was defined as: (1) A history of intracranial bleeding at any time; (2) Central nervous system tumor or intracranial vascular abnormality (such as aneurysm arteriovenous malformation) at any time; (3) Intracranial or spinal surgery or (4) Gastrointestinal bleeding within the past 6 months or major surgery within the last 30 days. 6. The researchers believe that there are diseases that may affect the normal conduct of the study or that do not cooperate well with the study or patients with significant risk factors such as alcohol or drug abusers with severe cancers of the liver, kidneys, lungs, endocrine systems (such as uncontrolled diabetes or thyroid disease) and neurological or blood system diseases. 7. Known or suspected pregnancy (baseline ss-hcg pregnancy test must be performed for women in reproductive stage); 8. Combined application of strong inducer or inhibitor of CYP P450 3A4, such as remifon; 9. Suspected aortic dissection; 10. Use of anticoagulant drugs during the study period; 11. Completely normal coronary variant angina pectoris; 12. Participated in a clinical study of another drug within 30 days; 13. Previous history of ischemic stroke; 14. Coronary artery bypass grafting has been performed in the past 5 years; 15. There are serious clinical laboratory abnormalities including: (1) Abnormal platelet count ( 600*10^9/L); (2) Three times the normal upper limit of ALT; (3) Blood creatinine > 220 micron /L; (4) Activated partial prothrombin time >1.3 times normal upper limit or INR > 1.5.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| cTnI/T;CK-MB;CK;BNP;ALT;hemoglobin;platelet;Erythrocyte count; | — |
Countries
China
Contacts
Public ContactMuwei Li
Fuwai Central China Cardiovascular Hospital
Outcome results
None listed